1. Home
  2. A randomized, open-label, controlled trial to evaluate the efficacy and safety of psilocybin in the treatment of treatment-resistant depression, administered together with SSRIs or after gradual discontinuation of SSRIs, compared to standard SSRI treatmen

A randomized, open-label, controlled trial to evaluate the efficacy and safety of psilocybin in the treatment of treatment-resistant depression, administered together with SSRIs or after gradual discontinuation of SSRIs, compared to standard SSRI treatmen

Symbol
ABM38
Rok początku realizacji
2024
Supervisor
Katarzyna Zakrzewska, Elżbieta Tatarzyńska
Project Title
A randomized, open-label, controlled trial to evaluate the efficacy and safety of psilocybin in the treatment of treatment-resistant depression, administered together with SSRIs or after gradual discontinuation of SSRIs, compared to standard SSRI treatment
Code
NZO
Financing Institution

Agencja Badań Medycznych

Medical Research Agency

Lead
prof. dr hab. Agata Szulc
Total awarded funds MUW ONLY
8 374 612,76
Total awarded funds FOR ALL
16 105 040,62